Richard Schilsky to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Richard Schilsky has written about Antimetabolites, Antineoplastic.
Connection Strength
1.812
-
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
Score: 0.211
-
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer. 2002 May; 2(1):51-2.
Score: 0.185
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.181
-
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49.
Score: 0.163
-
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20.
Score: 0.160
-
The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96.
Score: 0.154
-
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999 Mar 15; 85(6):1261-8.
Score: 0.149
-
Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):13-8.
Score: 0.144
-
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells. 1996 Jan; 14(1):29-32.
Score: 0.119
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
Score: 0.090
-
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
Score: 0.050
-
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75.
Score: 0.046
-
Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002 Mar; 40(3):201-11.
Score: 0.046
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.044
-
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs. 1998-1999; 16(3):275-8.
Score: 0.034
-
Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(2):163-6.
Score: 0.026
-
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
Score: 0.011